Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Cancer
.
2017 May 15;123(6):911-914.
doi: 10.1002/cncr.30532.
Epub 2017 Jan 17.
Authors
Maximilian Stahl
1
,
Amer M Zeidan
1
Affiliation
1
Section of Hematology, Department of Internal Medicine, Yale University and Yale Cancer Center, New Haven, Connecticut.
PMID:
28094843
DOI:
10.1002/cncr.30532
No abstract available
Publication types
Editorial
Comment
MeSH terms
Azacitidine*
DNA Methylation / drug effects
Histone Deacetylase Inhibitors*
Humans
Myelodysplastic Syndromes
Substances
Histone Deacetylase Inhibitors
Azacitidine